Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faldaprevir + tenofovir
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Faldaprevir + tenofovir** is a combination of two antiviral drugs: faldaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and tenofovir, a nucleotide reverse transcriptase inhibitor (NRTI) primarily used to treat HIV infection. The combination has been investigated for coadministration in patients coinfected with HCV and HIV, to address both viral infections simultaneously. Faldaprevir inhibits the HCV NS3/4A protease, preventing viral replication, while tenofovir impairs HIV reverse transcriptase, inhibiting viral DNA synthesis[1].
- Brand names
- VireadVemlidy
- Other names
- faldaprevir + tenofovir
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseNS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on faldaprevir + tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faldaprevir + tenofovir.